KLTO
Klotho Neurosciences, Inc.
Biotechnology
Market Cap$7M
5Y Perf.-59.1%
Build Your Comparison
Side-by-side financial analysisKLTO
ATHA
Try popular comparisons:
Stock Comparison
KLTO vs ATHA
Revenue, margins, valuation, and 5-year total return — side by side.
ATHA
Athira Pharma, Inc.
Biotechnology
Market Cap$17M
5Y Perf.-84.6%
KLTO vs ATHA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  KLTO |  ATHA |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $7M | $17M |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-11M | $-129M |
| Total Debt | $272K | $803K |
| Cash & Equiv. | $64K | $69M |
KLTO vs ATHA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
KLTO
ATHA
| Stock | Aug 24 | Mar 26 | Return |
|---|---|---|---|
| Klotho Neuroscience… (KLTO) | 100 | 40.9 | -59.1% |
| Athira Pharma, Inc. (ATHA) | 100 | 15.4 | -84.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KLTO vs ATHA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ATHA leads in 3 of 5 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Klotho Neurosciences, Inc. is the stronger pick specifically for operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
🥇ATHA emerged as the overall leader. Track its performance:
KLTO
Klotho Neurosciences, Inc.
The Long-Run Compounder
KLTO is the clearest fit if your priority is long-term compounding.
- -63.0% 10Y total return vs ATHA's -97.5%
- -112.1% ROA vs ATHA's -225.7%
Best for: long-term compounding
ATHA
Athira Pharma, Inc.
The Income Pick
ATHA carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.37
- EPS growth 2.0%
- Lower volatility, beta 1.37, Low D/E 2.9%, current ratio 1.88x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  ATHA | -64.6% revenue growth vs KLTO's -49.0% |
| Stability / Safety | ATHA | Beta 1.37 vs KLTO's 1.91, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ATHA | +40.0% vs KLTO's -81.0% |
| Efficiency (ROA) |  KLTO | -112.1% ROA vs ATHA's -225.7% |
KLTO vs ATHA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLKLTOLAGGINGATHA
ATHAAthira Pharma, Inc.
1leads
KLTOKlotho Neurosciences,…
3leads
6 Total Categories
CATEGORYLEADERvs ATHAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
KLTO1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
KLTO4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
KLTO5/6
Risk & VolatilityBeta, volatility, and downside exposure
ATHA2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
KLTO leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
KLTO and ATHA operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | KLTOKlotho Neuroscien… | ATHAAthira Pharma, In… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$8M | -$110M |
| Net IncomeAfter-tax profit | -$11M | -$129M |
| Free Cash FlowCash after capex | -$6M | -$52M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +72.9% | +24.8% |
KLTO leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — KLTO and ATHA each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | KLTOKlotho Neuroscien… | ATHAAthira Pharma, In… |
|---|---|---|
| Market CapShares × price | $7M | $17M |
| Enterprise ValueMkt cap + debt − cash | $8M | -$30M |
| Trailing P/EPrice ÷ TTM EPS | -1.19x | -0.17x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 6.19x | 0.37x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — KLTO and ATHA each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
KLTO leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
KLTO delivers a -113.7% return on equity — every $100 of shareholder capital generates $-114 in annual profit, vs $-4 for ATHA. ATHA carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to KLTO's 0.23x. On the Piotroski fundamental quality scale (0–9), KLTO scores 4/9 vs ATHA's 2/9, reflecting mixed financial health.
| Metric | KLTOKlotho Neuroscien… | ATHAAthira Pharma, In… |
|---|---|---|
| ROE (TTM)Return on equity | -113.7% | -3.8% |
| ROA (TTM)Return on assets | -112.1% | -2.3% |
| ROICReturn on invested capital | -2.4% | — |
| ROCEReturn on capital employed | -6.2% | -2.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 2 |
| Debt / EquityFinancial leverage | 0.23x | 0.03x |
| Net DebtTotal debt minus cash | $208,012 | -$68M |
| Cash & Equiv.Liquid assets | $63,741 | $69M |
| Total DebtShort + long-term debt | $271,753 | $803,000 |
| Interest CoverageEBIT ÷ Interest expense | -1.98x | — |
KLTO leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
KLTO leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KLTO five years ago would be worth $3,699 today (with dividends reinvested), compared to $224 for ATHA. Over the past 12 months, ATHA leads with a +40.0% total return vs KLTO's -81.0%. The 3-year compound annual growth rate (CAGR) favors KLTO at -28.2% vs ATHA's -48.9% — a key indicator of consistent wealth creation.
| Metric | KLTOKlotho Neuroscien… | ATHAAthira Pharma, In… |
|---|---|---|
| YTD ReturnYear-to-date | +19.1% | -37.6% |
| 1-Year ReturnPast 12 months | -81.0% | +40.0% |
| 3-Year ReturnCumulative with dividends | -63.0% | -86.6% |
| 5-Year ReturnCumulative with dividends | -63.0% | -97.8% |
| 10-Year ReturnCumulative with dividends | -63.0% | -97.5% |
| CAGR (3Y)Annualised 3-year return | -28.2% | -48.9% |
KLTO leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
ATHA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ATHA is the less volatile stock with a 1.37 beta — it tends to amplify market swings less than KLTO's 1.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ATHA currently trades 51.9% from its 52-week high vs KLTO's 15.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KLTOKlotho Neuroscien… | ATHAAthira Pharma, In… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.91x | 1.37x |
| 52-Week HighHighest price in past year | $2.45 | $8.36 |
| 52-Week LowLowest price in past year | $0.21 | $2.85 |
| % of 52W HighCurrent price vs 52-week peak | +15.6% | +51.9% |
| RSI (14)Momentum oscillator 0–100 | 61.9 | 38.4 |
| Avg Volume (50D)Average daily shares traded | 95K | 46K |
ATHA leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | KLTOKlotho Neuroscien… | ATHAAthira Pharma, In… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +1.6% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
KLTO leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ATHA leads in 1 (Risk & Volatility). 1 tied.
Best OverallKlotho Neurosciences, Inc. (KLTO)Leads 3 of 6 categories
Loading custom metrics...
KLTO vs ATHA: Frequently Asked Questions
6 questions · data-driven answers · updated daily
01Which is the better long-term investment — KLTO or ATHA?
Over the past 5 years, Klotho Neurosciences, Inc.
(KLTO) delivered a total return of -63. 0%, compared to -97. 8% for Athira Pharma, Inc. (ATHA). Over 10 years, the gap is even starker: KLTO returned -63. 0% versus ATHA's -97. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — KLTO or ATHA?
By beta (market sensitivity over 5 years), Athira Pharma, Inc.
(ATHA) is the lower-risk stock at 1. 37β versus Klotho Neurosciences, Inc. 's 1. 91β — meaning KLTO is approximately 40% more volatile than ATHA relative to the S&P 500. On balance sheet safety, Athira Pharma, Inc. (ATHA) carries a lower debt/equity ratio of 3% versus 23% for Klotho Neurosciences, Inc. — giving it more financial flexibility in a downturn.
03Which has better profit margins — KLTO or ATHA?
Klotho Neurosciences, Inc.
(KLTO) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Athira Pharma, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KLTO leads at 0. 0% versus 0. 0% for ATHA. At the gross margin level — before operating expenses — KLTO leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
04Which pays a better dividend — KLTO or ATHA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
05Is KLTO or ATHA better for a retirement portfolio?
For long-horizon retirement investors, Athira Pharma, Inc.
(ATHA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Klotho Neurosciences, Inc. (KLTO) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ATHA: -97. 5%, KLTO: -63. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
06What are the main differences between KLTO and ATHA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.